Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 14/20 | 0.69 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.56 |
| ▸ | MMP3 | P08254 | 2/20 | 0.56 |
| ▸ | MMP7 | P09237 | 2/20 | 0.56 |
| ▸ | ADAMTS1 | Q9UHI8 | 2/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866619 | 0.85 | ADAM17 (0.71) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6266539 | 0.80 | ADAM17 (0.57) | ADAM17 | |
| SCHEMBL6264308 | 0.79 | ADAM17 (0.56) | ADAM17 | |
| SCHEMBL6598359 | 0.79 | ADAM17 (0.70) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6595441 | 0.79 | ADAM17 (0.57) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL6596414 | 0.79 | ADAM17 (0.62) | ADAM17 | |
| SCHEMBL7402737 | 0.79 | ADAM17 (0.62) | ADAM17 | |
| SCHEMBL6593905 | 0.79 | ADAM17 (0.62) | ADAM17 | |
| SCHEMBL5883829 | 0.78 | ADAM17 (0.63) | ADAM17ADAMTS4MMP3MMP7ADAMTS1 | |
| SCHEMBL5883940 | 0.78 | ADAM17 (0.66) | ADAM17ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | claimed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | ADAM17 2/4885ADAMTS4 30/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.